Bayer (BAYRY) and Vanderbilt University Medical Center announced that they have entered a strategic five-year collaboration agreement to advance therapies from target identification through investigational new drug application. The agreement spans across all indications currently pursued by Bayer, initially focusing on cardiovascular and kidney diseases, two therapeutic areas with unmet medical need. The collaboration will leverage VUMC’s resource platform, including its datasets hosted in Vanderbilt’s BioVU collection of DNA and Plasma to enable data-driven insights and to accelerate discovery and development.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Bayer Stock Soars as U.S. Supreme Court Agrees to Review Roundup Appeal
- Bayer ‘welcomes’ Supreme Court review of Durnell litigation
- U.S. Supreme Court to hear Bayer’s appeal of Roundup lawsuits, Bloomberg says
- Bayer to acquire AT-01 and AT-05 from Attralus, terms undisclosed
- Bayer’s New Phase 4 ATTR-CM Study Tests Switching From Tafamidis to Acoramidis